Jan 31, 2023
Tuvik Beker, CEO of Pangea Biomed, is looking for more accurate biomarkers for oncology to determine better who might benefit from a specific drug. Their ENLIGHT platform is a pan-cancer, pan-treatment response predictor and can be used to find the best patient populations to give a new drug. They are also working with...
Jan 31, 2023
Tuvik Beker CEO of Pangea Biomed is looking for more accurate biomarkers for oncology to better determine who might benefit from a specific drug. Their ENLIGHT platform is a pan-cancer, pan-treatment response predictor and can be used to find the best patient populations to give a new drug. They are also working with...
Jan 30, 2023
Dr. Ira Spector is the CEO and Co-Founder of SFA Therapeutics, a clinical stage biopharmaceutical company leading the way as a fourth-generation microbiome company to treat inflammatory and autoimmune diseases. The first microbiome companies focused on fecal transplants, while the next innovation was probiotics. The...
Jan 30, 2023
Dr. Ira Spector is the CEO and Co-Founder of SFA Therapeutics, a clinical stage biopharmaceutical company leading the way as a fourth-generation microbiome company to treat inflammatory and autoimmune diseases. The first microbiome companies focused on fecal transplants, while the next innovation was probiotics. The...
Jan 27, 2023
Dr. Jula Inrig is the Chief Medical Officer of Travere Therapeutics and is eager to find innovative treatments for rare kidney diseases, which can be challenging to diagnose and have limited therapeutic options. In clinical trials, their lead candidate, sparsentan, reduces proteinuria significantly in patients with IgA...